Camrelizumab plus chemoradiotherapy for advanced esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests whether adding camrelizumab (an immune treatment) to standard chemoradiotherapy can control advanced esophageal squamous cell cancer. It is meant for people who have not had any prior whole-course cancer medicines for this cancer stage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed esophageal squamous cell cancer (from biopsy/pathology reports) and it is stage IVA or limited-metastasis stage IVB
- You have not had any prior cancer treatment that goes through the whole body for this esophageal cancer (including chemotherapy, targeted therapy, immunotherapy, or radiation)
- You are 18 to 75 years old, and your general condition is good (ECOG score 0 to 2)
- You have at least one measurable tumor area that can be followed during treatment
- Your blood counts and organ tests are within required ranges (white cells, neutrophils, platelets, hemoglobin, liver, and kidney) and you’re expected to live more than 3 months
- You cannot have certain serious problems, like repeatedly draining fluid around the lungs/heart/abdomen, significant bleeding, or certain immune conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether adding tislelizumab (an immunotherapy drug) to chemotherapy before a combined course of chemotherapy and radiation can better treat locally advanced, non-surgable esophageal squamous cell cancer. It’s for adults who cannot have surgery and may help shrink the cancer and improve control of the disease.
This trial tests a combination of radiation, chemotherapy (cisplatin and paclitaxel), and an immunotherapy drug called camrelizumab for patients with advanced esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if adding immunotherapy improves outcomes compared to standard treatment alone.
This trial tests whether giving the immunotherapy drug camrelizumab together with chemotherapy before surgery can help people with esophageal cancer avoid needing full removal of the esophagus. It aims to preserve the esophagus while still treating the cancer effectively.
This trial tests combining the immunotherapy drug carrelizumab with standard chemotherapy and radiation for people with advanced esophageal cancer that cannot be surgically removed. It aims to see if this combination can help shrink or control the tumor.
This trial tests a new immunotherapy drug (camrelizumab) combined with standard chemotherapy and radiation to treat advanced esophageal cancer while avoiding surgery if possible. The goal is to shrink the tumor and help you keep your esophagus working.
This study checks how well the immunotherapy drug camrelizumab works for people with advanced esophageal cancer outside of highly controlled trial settings. It may help doctors understand which patients benefit and how the treatment is used in everyday care.
Hear when a new Esophageal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.